Pfizer PFE is closing in on a potential $7.3 billion takeover of weight-loss drug developer Metsera MTSR, the Financial Times reported on Sunday, citing unidentified sources.

Pfizer, one of the largest pharmaceutical companies in the United States, will acquire New York City-based Metsera for $47.50 per share in cash, with an additional $22.50 per share contingent on the achievement of certain performance milestones, the newspaper said.

FT reported that the announcement could come as early as Monday, unless deal talks fall through.

Reuters could not immediately confirm the report. Pfizer and Metsera did not immediately respond to a Reuters request for comment outside regular business hours.

Talks to acquire Metsera come just months after the biotech firm’s blockbuster Nasdaq debut, underscoring surging investor appetite for companies developing next-generation weight-loss therapies. Some experts forecast that the global weight-loss drug market could be valued at $150 billion by the early 2030s.

The $47.50-per-share bid marks a roughly 42.5% premium over Metsera’s Friday closing price of $33.32, which pegged its market value at about $3.5 billion, according to LSEG data.